Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ontamalimab Maintenance in Crohn's Disease (CARMEN CD 307)
NCT03627091Phase 3Terminated
- Sponsor
- Takeda
- Start
- Feb 2019
- Primary completion
- Jun 2021
- Modality
- Monoclonal Antibodies
- Countries
- 34
01
Overview
Phase 3, randomised, double-blind trial of ontamalimab in Crohn's disease (3 arms), sponsored by Takeda. Primary endpoints: Number of Participants With Clinical Remission at Week 52 and Number of Participants With Enhanced Endoscopic Response at Week 52. Started Feb 2019; status: terminated.
02
Drugs
ontamalimab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT03627091.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03627091.